Contact
searchSearch
HMP Global
Login

Schizophrenia

.st0 {fill: #000;}
quiz
Quiz
Anosognosia in Schizophrenia: Coping Strategy or Symptom?
07/11/2022
According to Xavier Amador, PhD, anosognosia in schizophrenia is the neurocognitive symptom of unawareness of being ill. Additionally, according to the DSM-5-TR, anosognosia is what? Take the quiz to find out.
According to Xavier Amador, PhD, anosognosia in schizophrenia is the neurocognitive symptom of unawareness of being ill. Additionally, according to the DSM-5-TR, anosognosia is what? Take the quiz to find out.
According to Xavier Amador, PhD,...
07/11/2022
Psych Congress Network
.st0 {fill: #000;}
News
Cognitive Improvement Helps Drive Function Gains in Patients With Schizophrenia
07/05/2022
Cognitive gains partially mediate the relationship between cognitive enhancement therapy (CET) and improved functional capacity in people with schizophrenia, according to a new study.
Cognitive gains partially mediate the relationship between cognitive enhancement therapy (CET) and improved functional capacity in people with schizophrenia, according to a new study.
Cognitive gains partially...
07/05/2022
Psych Congress Network
.st0 {fill: #000;}
Rauch and Amador
Videos
DSM-5 Revisions, Educating Clinicians About Anosognosia
06/13/2022
Lindsay Galvin Rauch and Xavier Amador, PhD, tackle the importance of the DSM-5 revisions on helping to educate clinicians on diagnosing and treating patients with anosognosia.
Lindsay Galvin Rauch and Xavier Amador, PhD, tackle the importance of the DSM-5 revisions on helping to educate clinicians on diagnosing and treating patients with anosognosia.
Lindsay Galvin Rauch and Xavier...
06/13/2022
Psych Congress Network
.st0 {fill: #000;}
Rauch and Amador
Videos
The Importance of Collaborative Care in Anosognosia Treatment
06/08/2022
Lindsay Galvin Rauch and Xavier Amador, PhD, address how to incorporate the LEAP (Listen-Emphasize-Agree-Partner) approach in collaborative care as a way to improve relationships.
Lindsay Galvin Rauch and Xavier Amador, PhD, address how to incorporate the LEAP (Listen-Emphasize-Agree-Partner) approach in collaborative care as a way to improve relationships.
Lindsay Galvin Rauch and Xavier...
06/08/2022
Psych Congress Network
.st0 {fill: #000;}
Rauch and Amador
Videos
The Impact of Anosognosia and Noncompliance
05/20/2022
Lindsay Galvin Rauch and Xavier Amador, PhD, discuss how anosognosia impacts treatment noncompliance and the impact on family dynamics.
Lindsay Galvin Rauch and Xavier Amador, PhD, discuss how anosognosia impacts treatment noncompliance and the impact on family dynamics.
Lindsay Galvin Rauch and Xavier...
05/20/2022
Psych Congress Network
.st0 {fill: #000;}
Dr Leslie Citrome.
Videos
Part 2: Upcoming Schizophrenia Insights at APA Annual Meeting With Dr Citrome
05/17/2022
Leslie Citrome, MD, MPH, shares "what to expect" at this year's American Psychiatric Association 2022 Annual Meeting in the schizophrenia space.
Leslie Citrome, MD, MPH, shares "what to expect" at this year's American Psychiatric Association 2022 Annual Meeting in the schizophrenia space.
Leslie Citrome, MD, MPH, shares...
05/17/2022
Psych Congress Network
.st0 {fill: #000;}
Leslie Citrome, MD, MPH
Videos
Upcoming Schizophrenia Insights at APA Annual Meeting With Dr Citrome
05/12/2022
Leslie Citrome, MD, MPH, shares "what to expect" at this year's American Psychiatric Association 2022 Annual Meeting in the schizophrenia space.
Leslie Citrome, MD, MPH, shares "what to expect" at this year's American Psychiatric Association 2022 Annual Meeting in the schizophrenia space.
Leslie Citrome, MD, MPH, shares...
05/12/2022
Psych Congress Network
.st0 {fill: #000;}
Rauch and Amador
Videos
Defining and Diagnosing Anosognosia
05/01/2022
Lindsay Galvin Rauch interviews Xavier Amador, PhD, on defining and diagnosing anosognosia as it relates to severe mental illnesses, such as schizophrenia.
Lindsay Galvin Rauch interviews Xavier Amador, PhD, on defining and diagnosing anosognosia as it relates to severe mental illnesses, such as schizophrenia.
Lindsay Galvin Rauch interviews...
05/01/2022
Psych Congress Network
.st0 {fill: #000;}
Chepke
Videos
Overcoming Challenges in Schizophrenia Treatment
12/08/2021
In Part 2 of this video, Heather Flint, senior digital managing editor, Psych Congress Network, sits down with Psych Congress Steering Committee Member Craig Chepke, MD, FAPA, Medical Director, Excel Psychiatric Associates, Huntersville, NC,...
In Part 2 of this video, Heather Flint, senior digital managing editor, Psych Congress Network, sits down with Psych Congress Steering Committee Member Craig Chepke, MD, FAPA, Medical Director, Excel Psychiatric Associates, Huntersville, NC,...
In Part 2 of this video, Heather...
12/08/2021
Psych Congress Network
.st0 {fill: #000;}
Craig Chepke
Videos
Discussing Psychiatric Comorbidities and Treatment Options for Schizophrenia
12/06/2021
In Part 1 of this video, Heather Flint, senior digital managing editor, Psych Congress Network, sits down with Psych Congress Steering Committee Member Craig Chepke, MD, FAPA, Medical Director, Excel Psychiatric Associates, Huntersville, NC,...
In Part 1 of this video, Heather Flint, senior digital managing editor, Psych Congress Network, sits down with Psych Congress Steering Committee Member Craig Chepke, MD, FAPA, Medical Director, Excel Psychiatric Associates, Huntersville, NC,...
In Part 1 of this video, Heather...
12/06/2021
Psych Congress Network
.st0 {fill: #000;}
News
Schizophrenia Codes for Nursing Home Patients With Dementia Grew After Antipsychotic Reporting Began
12/01/2021
After the implementation of the CMS public reporting of nursing home antipsychotic use, the proportion of residents with different forms of dementia also diagnosed with schizophrenia increased — and more so among patients who were Black...
After the implementation of the CMS public reporting of nursing home antipsychotic use, the proportion of residents with different forms of dementia also diagnosed with schizophrenia increased — and more so among patients who were Black...
After the implementation of the...
12/01/2021
Psych Congress Network
.st0 {fill: #000;}
News
Veterans With Schizophrenia Benefit From LAI Therapy
11/16/2021
Several long-acting injectable (LAI) antipsychotic medications were associated with a reduced hazard of treatment discontinuation compared with oral olanzapine in US veterans with schizophrenia, according to a study results published in The...
Several long-acting injectable (LAI) antipsychotic medications were associated with a reduced hazard of treatment discontinuation compared with oral olanzapine in US veterans with schizophrenia, according to a study results published in The...
Several long-acting injectable...
11/16/2021
Psych Congress Network
.st0 {fill: #000;}
Dr Alva
Videos
Paliperidone Palmitate for Treatment of Schizophrenia
10/06/2021
In this video, Gus Alva, MD, Medical Director, ATP Clinical Research, Costa Mesa, California, discusses the recent FDA-approved long-acting injectable (LAI) paliperidone palmitate administered twice a year, for the treatment of schizophrenia....
In this video, Gus Alva, MD, Medical Director, ATP Clinical Research, Costa Mesa, California, discusses the recent FDA-approved long-acting injectable (LAI) paliperidone palmitate administered twice a year, for the treatment of schizophrenia....
In this video, Gus Alva, MD,...
10/06/2021
Psych Congress Network
.st0 {fill: #000;}
Leslie Citrome, MD, MPH
Videos
Current Research: Antipsychotics and Other Schizophrenia Treatments
10/01/2021
Leslie Citrome, MD, MPH, examines neurobiological targets, the current research regarding antipsychotics, and other schizophrenia treatment options.
Leslie Citrome, MD, MPH, examines neurobiological targets, the current research regarding antipsychotics, and other schizophrenia treatment options.
Leslie Citrome, MD, MPH,...
10/01/2021
Psych Congress Network
.st0 {fill: #000;}
Sanjai Rao, University of California
Videos
The Pharmacologic Properties of LAIs and Patient Preferences
09/21/2021
In this video, Sanjai Rao, MD, DFAPA, explains the pharmacologic properties of long-acting injectables (LAIs) and how this treatment option impacts patient preferences.
In this video, Sanjai Rao, MD, DFAPA, explains the pharmacologic properties of long-acting injectables (LAIs) and how this treatment option impacts patient preferences.
In this video, Sanjai Rao, MD,...
09/21/2021
Psych Congress Network
.st0 {fill: #000;}
Leslie Citrome, MD, MPH
Videos
Schizophrenia Symptoms, Hospitalizations Reduced With Psychological Rehabilitation
09/14/2021
Watch Leslie Citrome, MD, MPH, discuss the severity of functional deficits in schizophrenia and the importance of psychological rehabilitation.
Watch Leslie Citrome, MD, MPH, discuss the severity of functional deficits in schizophrenia and the importance of psychological rehabilitation.
Watch Leslie Citrome, MD, MPH,...
09/14/2021
Psych Congress Network
.st0 {fill: #000;}
Schizophrenia_cognitive_impairment_treatments
Percentage of Patients With Schizophrenia and Cognitive Dysfunction
08/25/2021
What percentage of patients with schizophrenia also have cognitive dysfunction? Take the quiz to find out!
What percentage of patients with schizophrenia also have cognitive dysfunction? Take the quiz to find out!
What percentage of patients with...
08/25/2021
Psych Congress Network
.st0 {fill: #000;}
News
Perceptual Distortions in Young Adulthood Predict Psychotic Symptoms Later
08/16/2021
New study reveals perceptual aberrations in young adulthood predicted increased levels of hallucinations, delusions, and total psychotic symptoms in midlife.
New study reveals perceptual aberrations in young adulthood predicted increased levels of hallucinations, delusions, and total psychotic symptoms in midlife.
New study reveals perceptual...
08/16/2021
Psych Congress Network
.st0 {fill: #000;}
Dr Rao
Videos
LAIs for Schizophrenia: Misconceptions and the Future of the Treatment
08/12/2021
Sanjai Rao, MD, DFAPA, discusses common misconceptions surrounding long-acting injectables (LAIs) and the future of the schizophrenia treatment option.
Sanjai Rao, MD, DFAPA, discusses common misconceptions surrounding long-acting injectables (LAIs) and the future of the schizophrenia treatment option.
Sanjai Rao, MD, DFAPA, discusses...
08/12/2021
Psych Congress Network
.st0 {fill: #000;}
Leslie Citrome, MD, MPH
Videos
Tools for Assessing Cognition in Patients With Schizophrenia
08/09/2021
Leslie Citrome, MD, MPH, discusses cognition in schizophrenia, breaks down the regions of the brain responsible for symptoms, and tools for assessing cognition.
Leslie Citrome, MD, MPH, discusses cognition in schizophrenia, breaks down the regions of the brain responsible for symptoms, and tools for assessing cognition.
Leslie Citrome, MD, MPH,...
08/09/2021
Psych Congress Network
.st0 {fill: #000;}
Dr Rao
Videos
Effective Communication Strategies to Implement LAIs Into Treatment Plans
08/04/2021
In this video, Sanjai Rao, MD, DFAPA, shares effective communications strategies for clinicians to implement long-acting injectables (LAIs) in their patients’ treatment plans.
In this video, Sanjai Rao, MD, DFAPA, shares effective communications strategies for clinicians to implement long-acting injectables (LAIs) in their patients’ treatment plans.
In this video, Sanjai Rao, MD,...
08/04/2021
Psych Congress Network
.st0 {fill: #000;}
Dr Sinjai Rao
Videos
LAIs Offer Opportunity for Increased Medication Adherence in Patients With Schizophrenia
06/30/2021
Sanjai Rao, MD, DFAPA, suggests long-acting injectables (LAIs) offer a treatment plan that leads to a greater opportunity for adherence in patients with schizophrenia over daily medications.
Sanjai Rao, MD, DFAPA, suggests long-acting injectables (LAIs) offer a treatment plan that leads to a greater opportunity for adherence in patients with schizophrenia over daily medications.
Sanjai Rao, MD, DFAPA, suggests...
06/30/2021
Psych Congress Network
.st0 {fill: #000;}
News
Reduced Antipsychotic Doses During Schizophrenia Maintenance Increase Relapse Risk
06/29/2021
Lowering an antipsychotic dose below the standard range recommended for acute stabilization appears to increase relapse risk and all-cause discontinuation during maintenance treatment in multi-episode schizophrenia.
Lowering an antipsychotic dose below the standard range recommended for acute stabilization appears to increase relapse risk and all-cause discontinuation during maintenance treatment in multi-episode schizophrenia.
Lowering an antipsychotic dose...
06/29/2021
Psych Congress Network
.st0 {fill: #000;}
News
Anticholinergic Medication Associated With Cognitive Impairment in Patients With Schizophrenia
06/23/2021
Cognitive impairments are associated with commonly prescribed psychotropic medications with anticholinergic properties for patients with schizophrenia, according to new research.
Cognitive impairments are associated with commonly prescribed psychotropic medications with anticholinergic properties for patients with schizophrenia, according to new research.
Cognitive impairments are...
06/23/2021
Psych Congress Network
.st0 {fill: #000;}
Dr Ballon
Videos
How to Improve Medication Adherence Rates Among Patients With Schizophrenia
06/14/2021
Jacob Ballon, MD, MPH, discusses why patients do not adhere to their medication treatment and tips for clinicians to improve medication adherence rates, in this expansion on his recent Psych Congress Elevate session.
Jacob Ballon, MD, MPH, discusses why patients do not adhere to their medication treatment and tips for clinicians to improve medication adherence rates, in this expansion on his recent Psych Congress Elevate session.
Jacob Ballon, MD, MPH, discusses...
06/14/2021
Psych Congress Network
.st0 {fill: #000;}
Videos
Best Practices for Matching Patients With Effective Antipsychotics and Mitigating Adverse Effects
06/08/2021
Jacob Ballon, MD, MPH, discusses key best practices for matching patients with schizophrenia with an effective antipsychotic, why patients do not adhere to their medication treatment, and mitigating adverse effects.
Jacob Ballon, MD, MPH, discusses key best practices for matching patients with schizophrenia with an effective antipsychotic, why patients do not adhere to their medication treatment, and mitigating adverse effects.
Jacob Ballon, MD, MPH, discusses...
06/08/2021
Psych Congress Network
.st0 {fill: #000;}
Quiz
Rare Genetic Biomarker May Indicate Which Mental Health Disorder?
05/25/2021
Take the quiz: Researchers recently identified a single letter change in the DNA code in a gene called PCHA3 that is associated with which mental health disorder?
Take the quiz: Researchers recently identified a single letter change in the DNA code in a gene called PCHA3 that is associated with which mental health disorder?
Take the quiz: Researchers...
05/25/2021
Psych Congress Network
.st0 {fill: #000;}
News
Oral Dissolving Film Rapidly Eases Acute Agitation in Patients with Schizophrenia
05/11/2021
An oral dissolving film for sublingual or buccal administration of dexmedetomidine was effective and well-tolerated for the rapid treatment of acute agitation in patients with schizophrenia, according to a poster presented at the 2021 APA...
An oral dissolving film for sublingual or buccal administration of dexmedetomidine was effective and well-tolerated for the rapid treatment of acute agitation in patients with schizophrenia, according to a poster presented at the 2021 APA...
An oral dissolving film for...
05/11/2021
Psych Congress Network
.st0 {fill: #000;}
Quiz
Percentage of Studied Population With Genetic Variant Linked to Schizophrenia
05/05/2021
Test your knowledge: Researchers recently identified a single letter change in the gene procadherin alpha 3 (PCDHA3) could result in early onset, treatment resistant schizophrenia. What percent of the Ashkenazi Jewish population studied had...
Test your knowledge: Researchers recently identified a single letter change in the gene procadherin alpha 3 (PCDHA3) could result in early onset, treatment resistant schizophrenia. What percent of the Ashkenazi Jewish population studied had...
Test your knowledge: Researchers...
05/05/2021
Psych Congress Network
.st0 {fill: #000;}
Early Onset, Treatment Resistant Schizophrenia Linked to Rare Gene Mutation
Videos
Early Onset, Treatment Resistant Schizophrenia Linked to Rare Gene Mutation
05/03/2021
In this video, Dr. Todd Lencz discusses how his study that identified a rare gene mutation that could result in schizophrenia can apply to future treatment and studies and one day help to develop a prognostic biomarker.
In this video, Dr. Todd Lencz discusses how his study that identified a rare gene mutation that could result in schizophrenia can apply to future treatment and studies and one day help to develop a prognostic biomarker.
In this video, Dr. Todd Lencz...
05/03/2021
Psych Congress Network
.st0 {fill: #000;}
News
Higher Brain Glutamate Levels May Act as Biomarker of Schizophrenia Severity
04/23/2021
Higher brain glutamate levels appear to be a biomarker of illness severity in patients with schizophrenia, according to a participant-level mega-analysis of proton magnetic resonance spectroscopy data.
Higher brain glutamate levels appear to be a biomarker of illness severity in patients with schizophrenia, according to a participant-level mega-analysis of proton magnetic resonance spectroscopy data.
Higher brain glutamate levels...
04/23/2021
Psych Congress Network
.st0 {fill: #000;}
Predicting High Utilization of Inpatient Psychiatric Services
04/20/2021
    Recently published research found that which of these
    Recently published research found that which of these
...
04/20/2021
Psych Congress Network
.st0 {fill: #000;}
News
Dementia Rate ‘Markedly Elevated’ in Older Adults With Schizophrenia
03/24/2021
More than a quarter of US adults with schizophrenia received a diagnosis of dementia before 66 years of age, according to a study published online ahead of print in JAMA Psychiatry. 
More than a quarter of US adults with schizophrenia received a diagnosis of dementia before 66 years of age, according to a study published online ahead of print in JAMA Psychiatry. 
More than a quarter of US adults...
03/24/2021
Psych Congress Network
.st0 {fill: #000;}
News
Caregivers of Patients With Schizophrenia Cite Need for Educational Resources
02/17/2021
Caregivers of patients with schizophrenia, an often overlooked target for education, feel they act as a mediator between the patient and their medical team and are responsible for the patient's therapeutic adherence, according to survey...
Caregivers of patients with schizophrenia, an often overlooked target for education, feel they act as a mediator between the patient and their medical team and are responsible for the patient's therapeutic adherence, according to survey...
Caregivers of patients with...
02/17/2021
Psych Congress Network
.st0 {fill: #000;}
News
Survey Reveals Clinicians’ Educational Needs in Schizophrenia Management
02/17/2021
Education on schizophrenia management should focus on the benefits of newer therapies, strategies to ease the patient transition from oral treatments, and ways to decrease key barriers, survey respondents said.
Education on schizophrenia management should focus on the benefits of newer therapies, strategies to ease the patient transition from oral treatments, and ways to decrease key barriers, survey respondents said.
Education on schizophrenia...
02/17/2021
Psych Congress Network
.st0 {fill: #000;}
Blog
Is Telepsychiatry Appropriate for Patients With Psychosis?
12/16/2020
Psych Congress Steering Committee member Edward Kaftarian, MD, discusses whether telepsychiatry is appropriate for patients with psychosis.
Psych Congress Steering Committee member Edward Kaftarian, MD, discusses whether telepsychiatry is appropriate for patients with psychosis.
Psych Congress Steering...
12/16/2020
Psych Congress Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use